ATE480260T1 - Stabile dosierungsform von phenylalanin-derivaten - Google Patents
Stabile dosierungsform von phenylalanin-derivatenInfo
- Publication number
- ATE480260T1 ATE480260T1 AT05786251T AT05786251T ATE480260T1 AT E480260 T1 ATE480260 T1 AT E480260T1 AT 05786251 T AT05786251 T AT 05786251T AT 05786251 T AT05786251 T AT 05786251T AT E480260 T1 ATE480260 T1 AT E480260T1
- Authority
- AT
- Austria
- Prior art keywords
- dosage form
- phenylalanine derivatives
- stable dosage
- phenylalanine
- derivatives
- Prior art date
Links
- 150000002993 phenylalanine derivatives Chemical class 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 abstract 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004045720A DE102004045720A1 (de) | 2004-09-21 | 2004-09-21 | Stabile Dosierungsform von Phenylalanin-Derivaten |
| PCT/EP2005/010143 WO2006032461A1 (de) | 2004-09-21 | 2005-09-20 | Stabile dosierungsform von phenylalanin-derivaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480260T1 true ATE480260T1 (de) | 2010-09-15 |
Family
ID=35429536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05786251T ATE480260T1 (de) | 2004-09-21 | 2005-09-20 | Stabile dosierungsform von phenylalanin-derivaten |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9089532B2 (enExample) |
| EP (1) | EP1799265B1 (enExample) |
| JP (1) | JP5054529B2 (enExample) |
| KR (1) | KR101228385B1 (enExample) |
| CN (1) | CN1993144B (enExample) |
| AT (1) | ATE480260T1 (enExample) |
| AU (1) | AU2005287582B2 (enExample) |
| BR (1) | BRPI0515533B8 (enExample) |
| CA (1) | CA2580639C (enExample) |
| DE (2) | DE102004045720A1 (enExample) |
| ES (1) | ES2347670T3 (enExample) |
| MX (1) | MX2007000399A (enExample) |
| RU (1) | RU2358736C2 (enExample) |
| WO (1) | WO2006032461A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| CA3174438A1 (en) | 2020-03-10 | 2021-09-16 | Redhill Biopharma Ltd. | Treatment of coronavirus infection |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA986594B (en) * | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
| MXPA01000553A (es) * | 1998-07-20 | 2002-04-24 | Wilex Ag | Nuevos inhibidores de urocinasas. |
| WO2003053999A2 (de) * | 2001-12-12 | 2003-07-03 | Wilex Ag | Selektive arylguanidinpeptide als urokinaseinhibitoren |
| DK1485345T3 (da) * | 2002-03-11 | 2008-11-03 | Curacyte Ag | Urokinaseinhibitorer, deres fremstilling og anvendelse |
| DE10225876A1 (de) * | 2002-06-11 | 2003-12-24 | Wilex Ag | Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren |
| AU2003253326A1 (en) * | 2002-07-25 | 2004-02-16 | Wilex Ag | Method for the production of phenylalanine derivatives |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
-
2004
- 2004-09-21 DE DE102004045720A patent/DE102004045720A1/de not_active Withdrawn
-
2005
- 2005-09-20 BR BRPI0515533A patent/BRPI0515533B8/pt not_active IP Right Cessation
- 2005-09-20 US US11/631,891 patent/US9089532B2/en active Active
- 2005-09-20 DE DE502005010237T patent/DE502005010237D1/de not_active Expired - Lifetime
- 2005-09-20 WO PCT/EP2005/010143 patent/WO2006032461A1/de not_active Ceased
- 2005-09-20 EP EP05786251A patent/EP1799265B1/de not_active Expired - Lifetime
- 2005-09-20 RU RU2007115064/15A patent/RU2358736C2/ru active
- 2005-09-20 CN CN2005800256252A patent/CN1993144B/zh not_active Expired - Fee Related
- 2005-09-20 ES ES05786251T patent/ES2347670T3/es not_active Expired - Lifetime
- 2005-09-20 AT AT05786251T patent/ATE480260T1/de not_active IP Right Cessation
- 2005-09-20 JP JP2007532821A patent/JP5054529B2/ja not_active Expired - Fee Related
- 2005-09-20 MX MX2007000399A patent/MX2007000399A/es active IP Right Grant
- 2005-09-20 AU AU2005287582A patent/AU2005287582B2/en not_active Ceased
- 2005-09-20 CA CA2580639A patent/CA2580639C/en not_active Expired - Fee Related
- 2005-09-20 KR KR1020077005447A patent/KR101228385B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0515533B1 (pt) | 2020-12-08 |
| CA2580639C (en) | 2013-04-23 |
| JP2008513529A (ja) | 2008-05-01 |
| EP1799265B1 (de) | 2010-09-08 |
| ES2347670T3 (es) | 2010-11-03 |
| US9089532B2 (en) | 2015-07-28 |
| KR20070054197A (ko) | 2007-05-28 |
| JP5054529B2 (ja) | 2012-10-24 |
| EP1799265A1 (de) | 2007-06-27 |
| MX2007000399A (es) | 2008-03-11 |
| AU2005287582A1 (en) | 2006-03-30 |
| KR101228385B1 (ko) | 2013-02-04 |
| DE102004045720A1 (de) | 2006-03-23 |
| RU2358736C2 (ru) | 2009-06-20 |
| DE502005010237D1 (de) | 2010-10-21 |
| WO2006032461A1 (de) | 2006-03-30 |
| RU2007115064A (ru) | 2008-10-27 |
| BRPI0515533B8 (pt) | 2021-05-25 |
| CA2580639A1 (en) | 2006-03-30 |
| CN1993144A (zh) | 2007-07-04 |
| AU2005287582B2 (en) | 2010-08-19 |
| BRPI0515533A (pt) | 2008-07-29 |
| CN1993144B (zh) | 2012-05-30 |
| US20070244127A1 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113192T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora | |
| CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
| LTPA2016016I1 (lt) | Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui | |
| EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| SE0301700D0 (sv) | Novel compounds | |
| NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
| TW200607505A (en) | Fused heterocyclic kinase inhibitors | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| DE602004020070D1 (de) | Thienopyrimidin-derivate als kaliumkanal-inhibitoren | |
| DK1255537T3 (da) | Farnesylproteintransferasehæmmere til behandling af brystcancer | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| ATE439355T1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
| ATE480260T1 (de) | Stabile dosierungsform von phenylalanin-derivaten | |
| ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone | |
| ATE435200T1 (de) | Guanidinophenylalanin-verbindungen als urokinase- inhibitoren | |
| MX2008007195A (es) | Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas. | |
| ATE451385T1 (de) | Verbindungen zur inhibierung von apoptose | |
| ATE312610T1 (de) | Liposomale formulierungen von phenylalanin- derivaten | |
| EA200600172A1 (ru) | Фармацевтическая композиция для интраназального введения пирибедила | |
| UA95930C2 (uk) | Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування | |
| DK1962822T3 (da) | Terapi af maligne neoplasier | |
| CY1113655T1 (el) | Παραγωγα 4-(3-αμινοπυραζολο) πυριμιδινης για χρηση ως αναστολεις κινασων τυροσινης στη θεραπευτικη αγωγη καρκινου | |
| EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |